The agreement provides a framework that combines cost containment with measures to support innovation (European Commission, 2016). It is participating in the new BeNeLuxA (with the Netherlands. Luxembourg and Austria) collaboration on joint HTA, horizon scanning, information exchange and pricing/reimbursement negotiation for new medicines.